New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
Recruiting
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) in approximately 48 pediatric participants (aged ≥6 and \<15 years at study entry) with moderate-to-severe AD. All eligible participants with AD will be treated with Dupixent® for 104 weeks according to locally approved D... Read More
Gender:
ALL
Ages:
Between 6 years and 14 years
Trial Updated:
06/21/2024
Locations: New York University Langone Health Site Number : 8400004, New York, New York
Conditions: Dermatitis Atopic
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Cholangiocarcinoma
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Recruiting
The purpose of this research study is to assess the safety and efficacy of fecal microbiota transplant (FMT) in the treatment of chronic pouchitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Chronic Pouchitis, Pouchitis
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Recruiting
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/21/2024
Locations: Memorial Sloan Kettering Suffolk - Commack (Consent Only), Commack, New York
Conditions: Adenocarcinoma of Lung
Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients
Recruiting
The investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with Occult Tethered Cord Syndrome (OTCS) and that the risks do not outweigh the benefit profile.
Gender:
ALL
Ages:
Between 2 years and 80 years
Trial Updated:
06/21/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Tethered Cord, Tethered Cord Syndrome, Occult Spina Bifida, Spina Bifida Occulta
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
Recruiting
The purpose of this research study is to investigate a shorter radiation treatment schedule for head and neck cancers in patients 70 years of age and older. Standard radiation treatment for head and neck patients normally requires that the patient travel to the hospital daily for 6-7 weeks to receive radiation treatment 5 days per week. This long course of radiation can lead to significant side effects resulting in some people being unable to complete the course of treatment. If this happens, a... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
06/21/2024
Locations: Mount Sinai Downtown Union Square, New York, New York
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty
Recruiting
Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the safety and efficacy of transcatheter arterial embolization in patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA). Eligible participants will receive geniculate artery embolization (GAE) using Embozene™ Color-Advanced Microspheres. Patients will be followed up for a total of 24 months after GAE.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
06/20/2024
Locations: NYU Langone Health, New York, New York
Conditions: Knee Pain
Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia
Recruiting
This is a pilot open-label study to evaluate the feasibility of conducting a clinical trial using sublingual dexmedetomidine sublingual film to treat hyperadrenergic autonomic crises in patients with Familial Dysautonomia at home. The primary aims are to examine the feasibility of performing a clinical trial using dexmedetomidine at home to terminate autonomic crisis, and refine the interventions and assessments used to evaluate autonomic crisis termination.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2024
Locations: NYU Langone Health, New York, New York
Conditions: Familial Dysautonomia
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
Recruiting
This study seeks to compare the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons at 5 distinct trial sites. This open-label, non-inferiority, head-to-head study design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of XR-B (and XR-NTX) as po... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: NYU Langone Health, New York, New York
Conditions: Opioid-use Disorder
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, New York, New York
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Recruiting
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Recruiting
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Clear Cell Renal Cell Carcinoma